May 27, 2025 BRIDGEWATER, N.J. — Amneal Pharmaceuticals has launched Exenatide 1.2 mL and 2.4 mL prefilled pen injection, an AP-rated generic equivalent for BYETTA.
– First ready-to-use, subcutaneous formulation of Bortezomib now available – Marks Amneal’s fourth 505(b)(2) injectable product launch in the last year BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal
– Mesalamine 800 mg delayed-release tablets, referencing ASACOL HD® – Lenalidomide capsules, referencing REVLIMID® BRIDGEWATER, N.J.–(BUSINESS WIRE)– Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the
January 23, 2025 Approval of three important therapies for dementia, oncology and gastrointestinal disease Granted 180-day exclusivity for memantine/donepezil extended-release capsules Tentative approval of rifaximin,
November 21, 2024 Potential first and only DHE autoinjector for tough-to-treat migraines and cluster headaches Exenatide approval highlights Amneal’s capabilities in developing GLP-1 injectables BRIDGEWATER,
Ready-to-Use Products from Amneal Allow You to Focus on What Matters Most A US-based company with strong roots in generic pharmaceuticals, Amneal is growing its
The Pharmacy500 is awarded to 500 supply chain businesses and associations that have made a significant impact on dispensing pharmacies in the U.S. over the
August 20, 2024 Propofol is an essential surgical anesthetic in hospitals that is in chronic shortage Complex emulsion injectable expands Amneal’s injectables portfolio BRIDGEWATER, N.J.–(BUSINESS
NACDS Total Store Expo 2024 August 17 – 19, 2024 | Boston, MA Discover new and innovative products, technology and services and find the partners
Stay informed on pharmacy supply chain news, market trends, and product releases by subscribing to RXinsider’s emails, newsletters, and publications. If building awareness with pharmacy management is part of your marketing strategy, consider advertising with RXinsider.
